Skip to main content
. Author manuscript; available in PMC: 2023 May 11.
Published in final edited form as: J Nat Prod. 2020 Mar 18;83(4):1249–1257. doi: 10.1021/acs.jnatprod.0c00038

Figure 6.

Figure 6.

Hypoxia-selective cytotoxicity of boholamide A (1) against U87MG glioblastoma cells. 1 is compared with standard glioblastoma treatments doxorubicin and temozolomide, showing that 1 is hypoxia-selective, whereas the standards are less cytotoxic to hypoxic cells.